Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Karen Lasch"'
Autor:
Vipul Jairath, Russell D. Cohen, Edward V. Loftus, Ninfa Candela, Karen Lasch, Bob G. Schultz
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Determining the relative cost-effectiveness between advanced therapeutic options for ulcerative colitis (UC) may optimize resource utilization. We evaluated total cost per response, cost per remission, and cost of safety events fo
Externí odkaz:
https://doaj.org/article/9b96c0d5caca472f93c3fe2e3e3f9beb
Autor:
Annie Guérin, Reema Mody, Valerie Carter, Charles Ayas, Haridarshan Patel, Karen Lasch, Eric Wu
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0145504 (2016)
OBJECTIVES:In 2009, the FDA issued a warning that omeprazole--a proton pump inhibitor (PPI)--reduces the antithrombotic effect of clopidogrel by almost half when taken concomitantly. This study aims to analyze the impact of the FDA Safety Communicati
Externí odkaz:
https://doaj.org/article/cbd9bdfabf0f41238ec715bae05ca6ab
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Autor:
Aimee Blake, Haridarshan Patel, Keith Syson Chan, Christian Agboton, Karen Lasch, Sam Keeping, Vipul Jairath
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 15:711-722
Objectives: Because only one head-to-head randomized trial of biologics for moderate-to-severe UC has been performed, indirect treatment comparisons remain important. This systematic review and net...
Autor:
Parambir S. Dulai, Brian G. Feagan, Bruce E. Sands, Jingjing Chen, Karen Lasch, Richard A. Lirio
Publikováno v:
Clinical Gastroenterology and Hepatology. 21:456-466.e7
We evaluated the value of post-induction fecal calprotectin (FCP) concentration as a biomarker in patients with ulcerative colitis (UC) treated with a biologic.This post hoc analysis of the GEMINI 1/GEMINI LTS (N = 620) and VARSITY (N = 771) trials e
Autor:
Karen Lasch, Dirk Lindner, Parambir S. Dulai, Laurent Peyrin-Biroulet, Haridarshan Patel, Dirk Demuth, Kristen A Hahn, Vipul Jairath
Publikováno v:
Journal of Crohn's & Colitis
Background Crohn’s disease [CD] is a chronic inflammatory bowel disease that, with progression, may require surgical intervention. Aim To determine whether vedolizumab treatment of CD earlier in the disease course [≤2 or ≤5 years of disease dur
Autor:
Corey A. Siegel, Dermot P B Mc Govern, Stephan R. Targan, Karen Lasch, Janine Bilsborough, Jonathan Braun, Carol J. Landers, Marla Dubinsky, Thierry Dervieux, Fred Princen, Ninfa Candela, Lori S. Siegel
Publikováno v:
Crohn's & Colitis 360. 3
Background Patients with Crohn’s disease (CD) are at risk of complications. Performance characteristics of a decision support tool assessing the risk of CD complications were evaluated. Methods CDPATH (formerly called the Personalized Risk and Outc
Autor:
Bruce E. Sands, Robert Hirten, Keith Sultan, David Faleck, Jenna L. Koliani-Pace, Shannon Chang, Michelle Luo, Eugenia Shmidt, David Hudesman, William J. Sandborn, Youran Gao, Parambir S. Dulai, Bo Shen, Monika Fischer, Preeti Shashi, Dana J. Lukin, A Weiss, Sunanda V. Kane, Gursimran Kochhar, Jiao Yang, Arun Swaminath, Joseph Meserve, Satimai Aniwan, Edward V. Loftus, Siddharth Singh, Adam Winters, Matthew Bohm, Shreya Chablaney, Zhongwen Huang, Sashidhar Varma, Nitin Gupta, Brigid S. Boland, Karen Lasch, Jean-Frederic Colombel, Corey A. Siegel
Publikováno v:
Inflammatory Bowel Diseases
Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns a
Autor:
Morris Barocas, Maria Rosario, Nathanael L. Dirks, Marc R. Gastonguay, Mark T. Osterman, Jayson D. Wilbur, Karen Lasch
Publikováno v:
Alimentary Pharmacology & Therapeutics
Background Prospectively designed studies assessing the exposure-response profile of vedolizumab are lacking. Observational exposure-response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly
Autor:
Mark T. Osterman, Vipul Jairath, Qasim Rana-Khan, Alexandra James, Diane Balma, Shailly Mehrotra, Lili Yang, Karen Lasch, Andres J. Yarur
Publikováno v:
Gastroenterology. 162:S-190